GABA Therapeutics is developing GRX-917, its lead drug candidate, across a broad range of therapeutic indications. The drug activates the production of brain neurosteroids which could benefit the lives of patients with life-altering neuropsychiatric, neurologic and pain disorders.
Many of these conditions represent some of the largest unmet medical needs in the United States and worldwide, including generalized anxiety disorder, anxious depression, postpartum depression, social anxiety disorder, panic disorder, pain and epilepsy. The company will be initiating pivotal registration trials in GAD in 2025, with approvals expected by 2028.
